Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1 MAD study of AG-348 in healthy volunteers
NCT02149966Phase 1Completed
- Sponsor
- Agios Pharmaceuticals
- Start
- May 2014
- Primary completion
- Nov 2014
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial in pyruvate kinase deficiency (PKD) comparing AG-348 with Placebo (2 arms). Primary endpoint: Incidence of adverse events at 29 days. Started May 2014; status: completed.
02
Drugs
mitapivat
03
Conditions
pyruvate kinase deficiency (PKD)
Beyond the preview
Go deeper on NCT02149966.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02149966.